Source: Halozyme Therapeutics, Inc. & reported by http://www.prnewswire.com/
SAN DIEGO, July 25, 2016 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that it has resumed the enrollment and dosing of patients in its ongoing Phase 1b trial evaluating its investigational new drug, PEGPH20, in combination with KEYTRUDA (pembrolizumab) in patients with advanced non-small cell lung and gastric cancers under a revised clinical protocol.
The revised protocol has been submitted to all institutional review boards (IRB) and is pending feedback from the FDA. The majority of IRBs have completed their review and approved the revised protocol allowing the study to resume.
The Phase 1b study will enroll up to approximately 80 patients at a number of leading sites in the United States. For more information, go to www.clinicaltrials.gov and reference NCT02563548.
Read more: http://www.prnewswire.com/news-releases/halozyme-resumes-patient-enrollment-and-dosing-in-pegph20-clinical-trial-with-keytruda-300303044.html